Dr. Reddy's Laboratories Limited, on Tuesday announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA), through an exchange filing.
Dr. Reddy’s Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.
Dr. Reddy's Laboratories on March 24 said it will surrender the certificate of registration of NBFC arm.
Dr Reddy's shares
The shares of Dr. Reddy's Laboratories Limited on Friday at 11:38 were at Rs 4,854.45, down by 0.077 per cent.
(To receive our E-paper on WhatsApp daily, please click here. To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)
